FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial
FGF-23 and hsCRP are biomarkers associated with increased CV risk, but these markers did not identify participants who preferentially benefited from treatment with canagliflozin.
Authors
- Daniela Grothe
- Filio Billia (ORCID: https://orcid.org/0000-0002-2824-1215)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Alanna Weisman (ORCID: https://orcid.org/0000-0003-3778-653X)
- Kim A. Connelly (ORCID: https://orcid.org/0000-0002-1031-3137)
- Ehsan Ghamarian (ORCID: https://orcid.org/0009-0002-4402-9932)
- Bruce Charles Neal (ORCID: https://orcid.org/0000-0002-0490-7465)
- Jacob A. Udell (ORCID: https://orcid.org/0000-0001-7402-9584)
- Aranya Punithan
- M. Maclean
Institutions
- St. Michael's Hospital (CA)
- University Health Network (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- Toronto Rehabilitation Institute (CA)
- Women's College Hospital (CA)
- Toronto General Hospital (CA)
- UNSW Sydney (AU)
- Ted Rogers Centre for Heart Research (CA)
- Occupational Cancer Research Centre (CA)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102276
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00